United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. decreased its position in United Therapeutics Co. (NASDAQ:UTHR) by 17.8% in the 4th quarter, Holdings Channel.com reports. The fund owned 2,635 shares of the biotechnology company’s stock after selling 569 shares during the period. E Fund Management Co. Ltd.’s holdings in United Therapeutics were worth $930,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in UTHR. Newbridge Financial Services Group Inc. acquired a new position in shares of United Therapeutics in the 4th quarter worth approximately $25,000. Brooklyn Investment Group bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $82,000. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 58 shares during the last quarter. Finally, Jones Financial Companies Lllp lifted its holdings in shares of United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 258 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Performance

UTHR opened at $315.91 on Friday. United Therapeutics Co. has a one year low of $221.53 and a one year high of $417.82. The stock’s fifty day moving average is $355.41 and its 200-day moving average is $360.08. The company has a market capitalization of $14.19 billion, a PE ratio of 13.87, a P/E/G ratio of 0.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same quarter in the previous year, the business earned $4.36 EPS. On average, equities research analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. UBS Group raised their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $388.25.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $360.76, for a total value of $3,607,600.00. Following the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $929,678.52. The trade was a 79.51 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the transaction, the director now owns 5,051 shares in the company, valued at $1,885,134.22. The trade was a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 116,464 shares of company stock valued at $42,396,244. Corporate insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.